Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-11-20 07:00 |
Biophytis annonce le succès de son augmentation de capital avec maintien du dr…
|
French | 233.3 KB | ||
| 2023-11-17 23:00 |
Biophytis announces receipt of Nasdaq Notice
|
English | 166.5 KB | ||
| 2023-11-17 23:00 |
Biophytis reçoit une notification du Nasdaq
|
French | 180.5 KB | ||
| 2023-11-06 07:00 |
Biophytis participe à BIO-Europe à Munich
|
French | 172.2 KB | ||
| 2023-10-30 06:00 |
Biophytis and Innovation Solutions Pharma sign a partnership agreement to accel…
|
English | 198.5 KB | ||
| 2023-10-30 06:00 |
Biophytis et Innovation Solutions Pharma signent un partenariat en vue d’accélé…
|
French | 201.7 KB | ||
| 2023-10-27 23:00 |
Biophytis receives notice of delisting from Nasdaq and announces it will reques…
|
English | 179.2 KB | ||
| 2023-10-27 23:00 |
Biophytis reçoit un avis de radiation du Nasdaq et annonce qu’elle fera appel d…
|
French | 187.0 KB | ||
| 2023-10-23 07:00 |
Biophytis announces the launch of a rights issue with maintenance of shareholde…
|
English | 252.8 KB | ||
| 2023-10-23 07:00 |
Biophytis annonce le lancement d’une augmentation de capital sous forme d’émiss…
|
French | 256.4 KB | ||
| 2023-09-27 23:18 |
Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an …
|
English | 251.8 KB | ||
| 2023-09-27 23:18 |
Biophytis publie ses comptes semestriels au 30 juin 2023 et fait le point sur …
|
French | 251.8 KB | ||
| 2023-09-25 07:00 |
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sa…
|
English | 290.8 KB | ||
| 2023-09-25 07:00 |
Biophytis et Skyepharma signent un partenariat pour la production de Sarconeos…
|
French | 294.0 KB | ||
| 2023-09-19 07:00 |
Biophytis provides an update on its early access programs for Sarconeos (BIO101…
|
English | 171.3 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
